Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Biomarkers Drive ICIs in Colon Cancer

December 14th 2020

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.

Frontline Pembrolizumab Granted Positive EU Opinion in Metastatic MSI-H, dMMR CRC

December 11th 2020

December 11, 2020 - The European Medicine Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for pembrolizumab monotherapy for the frontline treatment of adult patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Dr. Grothey on Investigational Combinations in MSI-High CRC

December 11th 2020

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Dr. Pawlik on Advances in Management of mCRC With Liver Metastases

December 9th 2020

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

Dr. Edith Mitchell Elected to Fellowship in the Royal College of Physicians of London

December 7th 2020

Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center – Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London.

Fruquintinib Enters Phase 3 Trial for Metastatic Colorectal Cancer

December 7th 2020

December 7, 2020 - The survival benefit of the novel agent fruquintinib will be tested during the phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer who are either intolerant to or have received 3 prior lines of chemotherapy.

Phase 2 Trial Expanded to Examine AGEN1181 Plus Balstilimab in Colon Cancer

December 3rd 2020

December 3, 2020 - A phase 2 trial has expanded to examine the use of the CTLA-4 antibody AGEN1181 in combination with the novel anti–PD-1 human monoclonal antibody balstilimab in patients with colon cancer.

Dr. Grothey on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

November 30th 2020

Axel Grothey, MD, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Dr. Pandalai on the Efficacy of Cytoreductive Surgery Plus HIPEC in Colorectal Peritoneal Carcinomatosis

November 25th 2020

Prakash Pandalai, MD, discusses the efficacy of aggressive cytoreductive surgery plus heated intraperitoneal chemotherapy in colorectal peritoneal carcinomatosis.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Dr. Eng on Features of High-Risk CRC

November 23rd 2020

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

Dr. Price on the Safety, Efficacy of AMG 510 in Advanced Gastrointestinal Cancers

November 21st 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

Dr. Eng on Contraindications for Oxaliplatin-Based Therapy in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses contraindications for oxaliplatin-based therapy in colorectal cancer.

Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months

November 19th 2020

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Dr. Eng on the Role of Preventive Screening in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of preventive screening in colorectal cancer.

Dr. Cavnar on the Roles of Chemotherapy and Surgery in Metastatic CRC

November 17th 2020

Michael J. Cavnar, MD, discusses the roles of chemotherapy and surgery in metastatic colorectal cancer.

Dr. Eng on the Role of Adjuvant Chemotherapy in CRC

November 16th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

CRC Treatment Enters New Era Where Personalized Care Is King

November 16th 2020

Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.

STING Agonist Plus Atezolizumab Could Expand Immunotherapy Benefit to Nonresponsive Advanced Solid Tumors

November 13th 2020

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC

November 11th 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.